Printer Friendly

Dopamine contamination of infused tyramine.

Clinical assessments of autonomic function often include tyramine (TYR) infusion. After uptake of TYR by sympathetic nerves via the cell membrane norepinephrine (NE) transporter and translocation of axoplasmic TYR into vesicles, NE exits the vesicles. Some of the NE enters the extracellular fluid and occupies adrenoceptors on cardiovascular smooth muscle cells, increasing blood pressure. A small proportion reaches the circulation, so that plasma NE concentrations increase (1-3).

Jacob et al. (4) reported an ~50-fold mean increase in plasma dopamine (DA) concentrations during intravenous TYR infusion, associated with "paradoxical" forearm vasodilation. We also noted high plasma DA concentrations in healthy volunteers during TYR infusion (5). When we assayed the catechol contents of the TYR infusate dispensed by our pharmacy [1 g/L (6.5 mmol/ L)], we found that the infusate contained ~50 [micro]mol/L DA, corresponding to 0.7% contamination (6). Whether during TYR infusion such contamination could actually raise plasma DA concentrations was unclear, as was whether, while stored as is customary in solution at 4 [degrees]C, TYR could be converted to DA. The present study examined these possibilities.

Solutions of TYR for infusion were prepared by the NIH Pharmaceutical Development Service, using TYR hydrochloride (Sigma) dissolved in sterile water, with pH ~9. The solutions were stored either in a refrigerator at 4 [degrees]C or in an ultra-low temperature freezer at -70 [degrees]C for up to 9 months and then were assayed for catechol content, including DA.

Infusate and arterial plasma concentrations of catechols were assayed (7), and hemodynamics were assessed before and during intravenous TYR infusion [6.5 [micro]mol (1 mg)/min] in a total of 34 adults who underwent TYR infusion as part of autonomic function testing. Of the 34 participants, 6 were healthy volunteers, 13 were patients with chronic orthostatic intolerance, 9 had neurogenic orthostatic hypotension, 5 had undergone thoracic sympathectomy, and 1 had an undiagnosed movement disorder. All gave informed written consent before participating in the study protocols, which were approved by the Intramural Research Board of the National Institute of Neurological Disorders and Stroke.

Blood samples were drawn after at least 15 min with the person supine. For arterial sampling, a brachial catheter was placed percutaneously after local anesthesia of the overlying skin. Arm venous blood was drawn through an indwelling intravenous catheter.

Forearm blood flow was measured by venous occlusion strain gauge plethysmography (Hokanson). The circulation of the hand was not excluded. Forearm vascular resistance was calculated from the ratio of mean arterial pressure to forearm blood flow. Blood pressure was monitored continuously, either via the arterial catheter or noninvasively by a finger oscillometric (Finometer or Portapres; TNO) or radial tonometric (Colin) device. Cardiac stroke volume was measured via impedance cardiography (Cardiodynamics), a noninvasive method we had validated previously (8).

Neurochemical and hemodynamic data were analyzed by linear regression and dependent-means t-tests. Values are reported as the mean (SE). A P value <0.05 defined statistical significance.

All of the 29 TYR infusates assayed after infusion into humans contained DA. During ~9 months of refrigerated (4 [degrees]C) storage of TYR solutions in the dark, DA in the infusate increased exponentially, from <25 to >600 nmol/L (r = 0.99; P <0.0001; Fig. 1A). In contrast, the DA concentration in TYR infusate stored frozen at -70 [degrees]C remained unchanged.

The neurochemical and hemodynamic results were unrelated to diagnosis. Below a DA concentration of 50 nmol/L in the infused TYR solution, there was no relationship between the increment in arterial plasma DA and the infusate DA concentration (Fig. 1B). Above an infusate DA concentration of 50 nmol/L, arterial plasma DA increased with the infusate DA concentration (r = 0.91 overall; P <0.001).


Infusion of TYR solutions with DA concentrations [less than or equal to] 50 nmol/L was associated with small increases in arterial plasma DA, larger increases in plasma NE, and even larger increases in plasma dihydroxyphenylglycol (DHPG; Table 1). TYR infusion also increased mean arterial pressure (t = 5.6; P <0.0001) and cardiac stroke volume (t = 4.2; P = 0.001) but did not affect the venous-arterial difference in plasma NE, heart rate, or total peripheral or forearm vascular resistance.

Increments in arterial plasma NE during infusion of uncontaminated TYR were correlated with increments in plasma DA (r = 0.70; P = 0.0003) and with increments in plasma DHPG (r = 0.45; P = 0.03). Increments in cardiac stroke volume were strongly positively correlated with those in arterial plasma NE (r = 0.83; P = 0.003).

TYR hydrochloride [1 g/L (6.5 mmol/L)] assayed immediately after being dissolved in deionized water contained ~42 nmol/L DA. During incubation at 37 [degrees]C in a water bath, the DA concentration decreased with a halftime of 224 min. When TYR hydrochloride was dissolved in tap water, the initial DA concentration was already low, at ~1300 ng/L, or 9 [micro]mol/L.

The results of this study show that TYR in aqueous solution undergoes nonenzymatic oxidation to DA. Over a period of 9 months of refrigerated storage of TYR solutions, the DA concentration increased exponentially, by ~25-fold. Over a similar time period, TYR in solutions stored at -70 [degrees]C the DA concentrations did not change.

Previously reported high plasma DA concentrations and forearm vasodilation during infusion of TYR solutions in humans therefore could have resulted from contamination of the infusates by DA produced during prolonged storage of TYR solution at 4 [degrees]C. In agreement with this notion, during intravenous TYR infusion into humans, the increment in the arterial plasma concentration of DA varied directly with the concentration of DA in the infusate. In one person, after receipt of TYR that had been stored for 9 months at 4 [degrees]C, the arterial plasma DA concentration exceeded 3 nmol/L, ~100 times higher than the typical concentration. The same person had a 30% decrease in forearm vascular resistance during the infusion. After making this observation, we did not think it ethically or scientifically sound to administer such contaminated TYR. Subsequently, we used TYR solutions stored at -70 [degrees]C.

From the results depicted in Fig. 1, the observed plasma DA increment in the study of Jacob et al. [650 ng/L (4.2 nmol/L) (4)] would have corresponded to ~2% contamination of the TYR infusate-well within quality-control limits. Infusion of relatively uncontaminated TYR in the present study produced much smaller increments in plasma DA that were not associated with forearm vasodilation. In healthy humans, intravenous DA infusion (0.5-2.0 [micro]g * [kg.sup.-1] * [min.sup.-1]) also does not affect forearm vascular resistance (9).

One might expect that forearm vascular resistance would increase during TYR infusion, because of local NE release. In humans, however, the pressor response to intravenous TYR reflects cardiac stimulation, not systemic vasoconstriction (10), as confirmed in the present study. Apparently, TYR releases NE from sympathetic nerves in the myocardium, where they are much more abundant than in skeletal muscle. If TYR released NE from sympathetic nerves in the forearm, then the venous-arterial difference for plasma NE in the arm should have increased; instead, the small arm venous-arterial difference for plasma NE did not change. Meanwhile, increments in cardiac stroke volume were strongly positively correlated with increments in arterial plasma NE.

During infusion of uncontaminated TYR, arterial plasma concentrations of DA, NE, and DHPG all increased in a correlated manner, with the largest increments in plasma DHPG and the smallest in plasma DA. One can understand these results in terms of TYR displacing NE from vesicular stores into the axoplasm, where the NE would undergo oxidative deamination to an aldehyde intermediate, followed by reduction of the aldehyde to DHPG (1,11,12). A small amount of vesicular NE would enter the extracellular fluid and occupy postsynaptic cardiovascular adrenoceptors or reach the plasma, explaining the strong positive correlation between increments in cardiac stroke volume and in arterial plasma NE concentrations. An even smaller amount of DA would enter the plasma, reflecting vesicular DA not yet converted to NE.

From the results of incubating TYR solutions at 37 [degrees]C, we inferred that DA formed from oxidation of TYR is itself rapidly oxidized, particularly in tap water solutions. Iron ions in tap water would be expected to catalyze oxidation of DA to dopaminechrome (13).

Before the discovery of tyrosine hydroxylase as the rate-limiting step in biosynthesis of catecholamines, researchers considered the possibility that endogenous catecholamines might arise from autooxidation of tyrosine. In the body, the rate of 3,4-dihydroxyphenylalanine (DOPA) formation by autooxidation of tyrosine was found to be negligible compared with the rate of formation by enzymatic catalysis. The present findings serve as a reminder that DA can be synthesized ex vivo by nonenzymatic oxidation of TYR. For both scientific and ethical reasons, investigators who carry out clinical studies involving TYR administration should assay DA concentrations to exclude contamination of the infusate. From a practical point of view, to minimize this contamination, we recommend that TYR be dissolved in deionized water and stored frozen at -70 [degrees]C.


(1.) Scriven AJI, Dollery CT, Murphy MB, Macquin I, Brown MJ. Blood pressure and plasma norepinephrine concentrations after endogenous norepinephrine release by tyramine. Clin Pharmacol Ther 1983;33:710-6.

(2.) Bianchetti MG, Minder I, Beretta-Piccoli C, Meier A, Weidmann P. Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertrtensioe subjects. Klin Wochenschr 1982;60:465-70.

(3.) Goldstein DS, Nurnberger J Jr, Simmons S, Gershon ES, Polinsky R, Keiser HR. Effects of injected sympathomimetic amines on plasma catecholamines and circulatory variables in man. Life Sci 1983;32:1057-63.

(4.) Jacob G, Costa F, Vincent S, Robertson D, Biaggioni I. Neurovascular dissociation with paradoxical forearm vasodilation during systemic tyramine administration. Circulation 2003;107:2475-9.

(5.) Goldstein DS, Holmes C. Metabolic fate of the sympathoneural imaging agent 6-[[sup.18]F]fluorodopamine in humans. Clin Exp Hypertens 1997;19:15561.

(6.) Goldstein DS, Holmes C, Jacob G, Costa F, Vincent S, Robertson D, et al. Vasodilation during systemic tyramine administration. Circulation 2004; 109: E17-8.

(7.) Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994;653:131-8.

(8.) Goldstein DS, Cannon RO, Zimlichman R, Keiser HR. Clinical evaluation of impedance cardiography. Clin Physiol 1986;6:235-51.

(9.) Os I, Kjeldsen SE, Westheim A, Lande K, Norman N, Hjermann I, et al. Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension. Scand J Clin Lab Invest 1987;47:371-7.

(10.) Meck JV, Martin DS, D'Aunno DS, Waters WW. Pressor response to intravenous tyramine is a marker of cardiac, but not vascular, adrenergic function. J Cardiovasc Pharmacol 2003;41:126-31.

(11.) Crout JR, Muskus AJ, Trendelenburg U. Effect of tyramine on isolated guinea-pig atria in relation to their noradrenaline stores. Br J Pharmacol 1962;18:600-11.

(12.) Brodie BB, Cho AK, Stefano FJ, Gessa GL. On mechanisms of norepinephrine release by amphetamine and tyramine and tolerance to their effects. Adv Biochem Psychopharmacol 1969;1:219-38.

(13.) Hermida-Ameijeiras A, Mendez-Alvarez E, Sanchez-Iglesias S, Sanmartin-Suarez C, Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem Int 2004;45:103-16.

Previously published online at D01: 10.1373/clinchem.2005.054361

Courtney Holmes, [1] * Jeffrey Moak, [2] Basil Eldadah, [1] Ella Zimmerly, [1] Yehonatan Sharabi, [1] and David S. Goldstein [1] [1] Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; [2] Children's National Medical Center, Washington, DC; * address correspondence to this author at: Bldg. 10, Room 6N250, 10 Center Dr., MSC-1620, Bethesda, MD 20892-1620; fax 301-402-0180, e-mail
Table 1. Neurochemical and hemodynamic values during
supine rest and after 10 min of TYR infusion (infusate DA
[less than or equal to] 50 nmol/L).

 Value Baseline (a)

[DA.sub.a], (b) ng/L 0.07 (0.01) [n = 12]
[NE.sub.a], ng/L 1.17 (0.19) [n = 13]
[NE.sub.v], ng/L 1.09 (0.26) [n = 9]
AV diff NE, ng/L 0.02 (0.08) [n = 9]
[DHPG.sub.a], ng/L 4.30 (0.37) [n = 13]
[DHPG.sub.v], ng/L 4.42 (0.78) [n = 9]
Heart rate, beats/min 67 (5) [n = 10]
Stroke volume, mL 82 (7) [n = 10]
Cardiac output, L/min 5.3 (0.3) [n = 10]
Total peripheral 1694 (171) [n = 10]
 mmHg x min/L
MAP, mmHg 108 (4) [n = 23]
FBF, mL x 4.2 (0.4) [n = 23]
 [min.sup.-1] x
FVR units 32 (5) [n = 23]

 Value TYR infusion (a)

[DA.sub.a], (b) ng/L 0.10 (0.02)(c) [n = 12]
[NE.sub.a], ng/L 1.67 (0.32) (c) [n = 13]
[NE.sub.v], ng/L 1.77 (0.49) (c) [n = 11]
AV diff NE, ng/L 0.17 (0.36) [n = 10]
[DHPG.sub.a], ng/L 7.82 (0.76) (d) [n = 13]
[DHPG.sub.v], ng/L 7.49 (1.18) (c) [n = 10]
Heart rate, beats/min 63 (4) [n = 10]
Stroke volume, mL 94 (8) (e) [n = 10]
Cardiac output, L/min 5.7 (0.4) [n = 10]
Total peripheral 1756 (172) [n = 10]
 mmHg x min/L
MAP, mmHg 119 (5) (d) [n = 23]
FBF, mL x 4.1 (0.3) [n = 23]
 [min.sup.-1] x
FVR units 34 (5) [n = 23]

(a) Values are the mean (SE), with the numbers in brackets
indicating the numbers of individuals.

(b) [DA.sub.a], arterial plasma DA; [NE.sub.a], arterial plasma
NE; AV diff, venous-arterial difference; DHPGa, arterial plasma
DHPG; MAP,NE; [NE.sub.v], arm venous plasma mean arterial pressure;
FBF, forearm blood flow; FVR, forearm vascular resistance.

(c-e) Significant difference from baseline: (c) P <0.05;
(d) P <0.001; (e) P <0.01.
COPYRIGHT 2005 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technical Briefs
Author:Holmes, Courtney; Moak, Jeffrey; Eldadah, Basil; Zimmerly, Ella; Sharabi, Yehonatan; Goldstein, Davi
Publication:Clinical Chemistry
Date:Sep 1, 2005
Previous Article:Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset preeclampsia.
Next Article:Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |